The company’s participation includes both the virtual session and a series of one-on-one meetings with investors in New York. Interested parties can access a live webcast of the presentation through the investor relations section of the Tyra Biosciences website, where a replay will also be hosted following the event.

Tyra Biosciences continues to advance its proprietary SNÅP platform, which facilitates rapid drug design through iterative molecular snapshots. The firm’s current development efforts center on three primary candidates: the FGFR3 inhibitor dabogratinib, the FGFR4/3-biased inhibitor TYRA-430 for hepatocellular carcinoma, and the FGFR1/2/3 inhibitor TYRA-200, currently under investigation for metastatic intrahepatic cholangiocarcinoma.